{"id":62925,"date":"2014-10-31T20:18:20","date_gmt":"2014-11-01T00:18:20","guid":{"rendered":"http:\/\/countingpips.com\/?p=62925"},"modified":"2014-10-31T20:18:20","modified_gmt":"2014-11-01T00:18:20","slug":"why-the-did-csl-limited-share-price-rise-today","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/forex\/2014\/10\/why-the-did-csl-limited-share-price-rise-today\/","title":{"rendered":"Why the Did CSL Limited Share Price Rise Today?"},"content":{"rendered":"
October 31, 2014<\/div>
\r\n<\/div><\/div>

By MoneyMorning.com.au<\/u><\/a><\/p>\n

What Happened to the CSL Share Price?<\/h2>\n

CSL Limited [ASX:CSL] is a biopharmaceutical company involved in research, manufacturing and product marketing. CSL develops a range of products to treat viral and bacterial illnesses, bleeding disorders and coagulation disorders such as blood clotting.<\/p>\n

The CSL share price closed 1.30% higher on Friday.<\/p>\n

Why Did This Happen to CSL Shares?<\/h2>\n

Recently CSL acquired the Novartis influenza vaccine business for US$275 million. Settlement will occur in the middle of 2015.<\/p>\n

The $950 million share buyback plan will continue, as CSL are using surplus cash for the sale. <\/p>\n

What Now For CSL?<\/h2>\n

The Novartis influenza business will be combined with the company\u2019s subsidiary, bioCSL. <\/p>

\r\n
\r\n

Free Reports:<\/p><\/div>\r\n

\r\n

<\/a>\r\n\t Get Our Free Metatrader 4 Indicators<\/u><\/b><\/a> - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter<\/p>

\r\n
\r\n
\r\n

<\/a>\r\n\t Get our Weekly Commitment of Traders Reports<\/u><\/b><\/a> - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.<\/p>

\r\n<\/div>\r\n

\r\n
<\/div>\n

Combing these two businesses will make CSL is the number two player in the US$4 billion influenza vaccine industry. The growth potential of this increases the value of CSL. Sales could be US$1billion per year over the next three to five years.<\/p>\n

In additional, CSL has been exploring a plasma treatment for the Ebola virus at the request of the Gates Foundation. <\/p>\n

In the two weeks since the Ebola announcement, followed by the Novartis acquisition, the share price has increased almost 8%.<\/p>\n

CSL is now reaching $80 per share.<\/p>\n

Some analysts believe CSL\u2019s market share will be tested this year and next. Baxter International Inc. [NYSE:BAX] is soon to have immunoglobin product HyQvia approved in the US. This product could take market share from CSL\u2019s Hizentra.<\/p>\n

However, the new business may offset investors\u2019 fears of greater competition. <\/p>\n

This new high will see many investors taking profits, so be prepared for a fall in the share price in the coming weeks. CSL regularly dips with market news, so time your entry into this stock carefully. <\/p>\n

CSL remains a solid defensive stock.<\/p>\n

Shae Smith+<\/a>
\nEditor, Money Weekend<\/em><\/strong> <\/p>\n

Join Money Morning on Google+ <\/span><\/a><\/strong><\/p>\n

The post Why the Did CSL Limited Share Price Rise Today?<\/a> appeared first on Stock Market News, Finance and Investments | Money Morning Australia<\/a>.<\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n


\nBy MoneyMorning.com.au<\/u><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

By MoneyMorning.com.au What Happened to the CSL Share Price? CSL Limited [ASX:CSL] is a biopharmaceutical company involved in research, manufacturing and product marketing. CSL develops a range of products to treat viral and bacterial illnesses, bleeding disorders and coagulation disorders such as blood clotting. The CSL share price closed 1.30% higher on Friday. Why Did […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-62925","post","type-post","status-publish","format-standard","hentry","no-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/posts\/62925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/comments?post=62925"}],"version-history":[{"count":0,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/posts\/62925\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/media?parent=62925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/categories?post=62925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/tags?post=62925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}